Deucravacitinib, a selective TYK2 inhibitor, demonstrates efficacy comparable to biologics while offering meaningful improvements in symptoms and quality of life for patients with psoriatic arthritis.
In an interview with Pharmacy Times, Philip J. Mease, MD, director of rheumatology research at Providence Swedish Medical Center and clinical professor at the University of Washington School of Medicine, Seattle, discussed the clinical significance of the FDA approval of deucravacitinib (Sotyktu; Bristol Myers Squibb), the first and only tyrosine kinase 2 (TYK2) inhibitor
Mease explained that although TYK2 is part of the Janus kinase inhibitor family, it functions through a more selective mechanism, targeting IL-23, IL-12, and interferon pathways—key cytokines involved in inflammatory and autoimmune processes. This selectivity differentiates deucravacitinib from broader Janus kinase inhibitors and may offer a more targeted therapeutic approach in immune-mediated diseases such as psoriasis and psoriatic arthritis.
From an efficacy standpoint, results from the phase 3 POETYK PsA-1 (NCT04908202) and PsA-2 (NCT04908189) trials demonstrated that approximately 54% of patients achieved an American College of Rheumatology 20 (ACR20) response at week 16, compared with 34% to 39% in placebo groups. Mease noted that these outcomes are consistent with response rates observed with established biologic therapies, including tumor necrosis factor, IL-17, and IL-23 inhibitors. Importantly, deucravacitinib demonstrated benefits across joint and skin manifestations, as well as improvements in physical function and overall quality of life.
Mease emphasized that although clinicians often rely on clinical end points such as ACR20 or Psoriasis Area and Severity Index scores, patients prioritize symptom relief, including reductions in pain, fatigue, and functional limitations. Patient-reported outcomes from clinical trials showed meaningful improvements in these areas, reinforcing the therapy’s relevance in real-world care.
“What patients come into the clinic with are pain, fatigue, and difficulty functioning… these are the key elements that are important for patients.” – Philip J. Mease, MD
For pharmacists, these findings underscore the importance of understanding mechanistic differences and patient-centered outcomes when counseling individuals with psoriatic arthritis. Deucravacitinib represents a novel oral option that combines targeted immunologic activity with clinically meaningful improvements in symptoms and quality of life, supporting its role as an additional therapeutic option in a complex treatment landscape.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
